Multiple Sclerosis Resource Centre

Welcome to the Multiple Sclerosis Resource Centre. This website is intended for international healthcare professionals with an interest in Multiple Sclerosis. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

Attitudes to cannabis and patterns of use among Canadians with multiple sclerosis

Multiple Sclerosis and Related Disorders, November 2016, Pages 123 - 126

Abstract

Background

Canada has the highest incidence of MS worldwide. Anecdotal evidence reveals that people with MS smoke, ingest or vaporize cannabis for a multiplicity of reasons. With the legal situation in relation to use currently in flux, we undertook a study investigating patterns of use amongst people with MS and their attitudes towards the drug.

Methods

A consecutive sample of people with MS (n=246) attending a neurology (n=118) and a neuropsychiatry (n=107) clinic was enrolled and asked to complete a questionnaire containing demographic, disease and cannabis related variables.

Results

Of the 246 people approached, 225 (91.8%) agreed to participant. Attitude towards cannabis revealed that 122 (54.3%) participants approved of the drug while 75 (33.2%) were neutral. Legalization was endorsed by 98 (43.7%) participants, while 98 (43.7%) were in favour of legalization for medical use only. Current use was endorsed by 44 (19.5%) people with 125 (56.1%) reporting lifetime use. If cannabis were legal, 113 (50.2%) participants would use it. The most common symptoms for which cannabis was being used were: sleep (86%), pain (75%), anxiety (73%) and spasticity (68%). Participants attending the neuropsychiatry clinic were more likely to use cannabis for managing depression (χ2=4.99; p=0.03) and pain (χ2=3.85; p=0.05).

Conclusion

There is a wide acceptance of cannabis within the MS patient community. One in five people currently use the drug for reasons that differ between neuropsychiatry and neurology clinics. Use could potentially more than double if the drug were legalized.

Highlights

  • 91.8% of people approached agreed to participate in the survey.
  • 54.3% of participants approved of cannabis use, while 33.2% remained neutral.
  • 19.5% of participants use cannabis.
  • 50.2% of the remaining participants would use it if the drug were legal.
  • Participants attending the neuropsychiatry clinic were more likely to use cannabis for managing depression (χ2=4.99; p=0.03) and pain (χ2=3.85; p=0.05).

Keywords: Multiple sclerosis, Cannabis, Survey, Neurology, Psychiatry, Cannabis use.

Footnotes

a Sunnybrook Health Sciences Centre, Toronto, ON, Canada

b University of Toronto, Toronto, Ontario, Canada

Corresponding author at : Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5.